SQZ logo

SQZ Biotechnologies (SQZ) Stock

Profile

Full Name:

SQZ Biotechnologies Company

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 October 2020

Indexes:

Not included

Description:

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Aug 04, 2023

Recent annual earnings:

Mar 22, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

July 07, 2023

Analyst ratings

Recent major analysts updates

02 Dec '22 HC Wainwright & Co.
Neutral
01 Dec '22 Chardan Capital
Buy
01 Dec '22 B of A Securities
Underperform
10 Nov '22 Chardan Capital
Buy
20 Oct '22 HC Wainwright & Co.
Buy
06 Oct '22 BTIG
Buy
25 May '22 Chardan Capital
Buy
08 Jan '21 Evercore ISI Group
Outperform
24 Nov '20 Stifel
Buy
24 Nov '20 BTIG
Buy

Screeners with SQZ included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Serica Energy says 2025 outlook is ‘promising'
Serica Energy says 2025 outlook is ‘promising'
Serica Energy says 2025 outlook is ‘promising'
SQZ
proactiveinvestors.co.uk21 January 2025

Serica Energy PLC (AIM:SQZ) told investors that its outlook for 2025 is “promising”, highlighting ongoing work to “increase asset reliability”. The North Sea oil and gas producer reported its performance for 2024, in which amounted to 34,600 barrels of oil equivalent per day (boepd), down from 40,100 boepd, due to unplanned downtime for the Triton floating production facilities.

Serica Energy expects to remedy “clearly disappointing” recent production performance
Serica Energy expects to remedy “clearly disappointing” recent production performance
Serica Energy expects to remedy “clearly disappointing” recent production performance
SQZ
proactiveinvestors.co.uk07 January 2025

Serica Energy PLC (AIM:SQZ) described its second-half production as clearly disappointing and below the potential of its assets. The North Sea oiler, in a statement, said that production in 2024 averaged 34,600 barrels of oil equivalent per day (boepd) for 2024, with contributions of 19,800 boepd from the Bruce Hub, 9,000 boepd from the Triton Hub, and 5,800 boepd from other assets.

Serica Energy reports temporary production halt at Triton
Serica Energy reports temporary production halt at Triton
Serica Energy reports temporary production halt at Triton
SQZ
proactiveinvestors.co.uk29 October 2024

Serica Energy PLC (AIM:SQZ) has reported a temporary production halt on the Triton Floating Production Storage and Offloading (FPSO) facility, due to a potential gas seal failure. The issue, which was identified on October 26, did not result in any hydrocarbon leak, and the facility's operator, Dana Petroleum, is actively working to diagnose and execute the required repairs, Serica told investors.

Serica Energy reveals bumper volumes from Bittern well
Serica Energy reveals bumper volumes from Bittern well
Serica Energy reveals bumper volumes from Bittern well
SQZ
proactiveinvestors.co.uk02 October 2024

Serica Energy PLC (AIM:SQZ) told investors its Bittern B6 well, in the UK North Sea, is now producing oil and gas at a combined gross rate of approximately 8,000 barrels of oil equivalent per day (boepd). The well, a side-track drilled from an existing well in the Triton field earlier this year, is flowing back to the Triton floating production vessel (FPSO).

Serica Energy calls UK oil and gas tax regime “unjustifiably punitive”
Serica Energy calls UK oil and gas tax regime “unjustifiably punitive”
Serica Energy calls UK oil and gas tax regime “unjustifiably punitive”
SQZ
proactiveinvestors.co.uk10 September 2024

Serica Energy PLC (AIM:SQZ) chief executive Chris Cox described the North Sea fiscal regime as “unjustifiably punitive” and said it may make future investment on the UK continental shelf challenging. “What is clear is that, thanks to our investment in our assets and our lean operating model, our producing assets remain cash generative, even after paying taxes at a rate of 75% today and due to rise to 78% from 1 November.

SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates
SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates
SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates
SQZ
Zacks Investment Research10 May 2023

SQZ Biotechnologies Company (SQZ) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.75 per share a year ago.

FAQ

  • What is the primary business of SQZ Biotechnologies?
  • What is the ticker symbol for SQZ Biotechnologies?
  • Does SQZ Biotechnologies pay dividends?
  • What sector is SQZ Biotechnologies in?
  • What industry is SQZ Biotechnologies in?
  • What country is SQZ Biotechnologies based in?
  • When did SQZ Biotechnologies go public?
  • Is SQZ Biotechnologies in the S&P 500?
  • Is SQZ Biotechnologies in the NASDAQ 100?
  • Is SQZ Biotechnologies in the Dow Jones?
  • When was SQZ Biotechnologies's last earnings report?
  • When does SQZ Biotechnologies report earnings?
  • Should I buy SQZ Biotechnologies stock now?

What is the primary business of SQZ Biotechnologies?

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

What is the ticker symbol for SQZ Biotechnologies?

The ticker symbol for SQZ Biotechnologies is NYSE:SQZ

Does SQZ Biotechnologies pay dividends?

No, SQZ Biotechnologies does not pay dividends

What sector is SQZ Biotechnologies in?

SQZ Biotechnologies is in the Healthcare sector

What industry is SQZ Biotechnologies in?

SQZ Biotechnologies is in the Biotechnology industry

What country is SQZ Biotechnologies based in?

SQZ Biotechnologies is headquartered in United States

When did SQZ Biotechnologies go public?

SQZ Biotechnologies's initial public offering (IPO) was on 30 October 2020

Is SQZ Biotechnologies in the S&P 500?

No, SQZ Biotechnologies is not included in the S&P 500 index

Is SQZ Biotechnologies in the NASDAQ 100?

No, SQZ Biotechnologies is not included in the NASDAQ 100 index

Is SQZ Biotechnologies in the Dow Jones?

No, SQZ Biotechnologies is not included in the Dow Jones index

When was SQZ Biotechnologies's last earnings report?

SQZ Biotechnologies's most recent earnings report was on 4 August 2023

When does SQZ Biotechnologies report earnings?

The date for SQZ Biotechnologies's next earnings report has not been announced yet

Should I buy SQZ Biotechnologies stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions